The Philippines said on Friday the anti-dengue vaccine Dengvaxia may be connected to three deaths in the country, according to a government-ordered inquiry, and that the drug is not ready for mass immunisation. French drug maker Sanofi revealed in November that Dengvaxia - the world's first dengue vaccine - might increase the risk of severe disease in people who had never been exposed to the virus. The news prompted an uproar in the Philippines, where more than 800,000 school-age children had been vaccinated in 2016. Sanofi officials were not immediately available for comment on the government announcement. The Philippine Health Ministry halted Dengvaxia immunisations in November. It formed a 10-member panel of experts to determine if the drug was directly connected to the deaths of 14 children after they were given the vaccine. It found it may have been connected to the deaths of three. "Three cases were found to have causal association. They died of dengue even (though) they were … [Read more...] about Philippines says anti-dengue vaccine may be connected to three deaths
Dengue vaccine sanofi
The world's first dengue fever vaccine, developed by French drugmaker Sanofi, reduced cases of the disease by 56.5 percent during a clinical study conducted in five Asian countries, including Vietnam. The vaccine also slashed the severe cases of dengue by 88.5 percent and the risk of hospitalization by 67 percent during the study, Dr. Tran Ngoc Huu, a key researcher of the vaccines impact in Vietnam, announced during a seminar in Ho Chi Minh City on Monday. The study -- conducted on 10,275 children aged 2-14 across Indonesia, Malaysia, Philippines, Thailand and Vietnam -- determined that the three-dose vaccine was safe and had no serious side effects, Huu said. The vaccine provided 13 months of inoculation against the virus after the third dose was administered, adding that his team will closely monitor the duration of the vaccine's efficacy until November 2017. "We are moving towards the dengue vaccine. This vaccine, in coordination with other preventive measures, will make the fight … [Read more...] about Trial dengue vaccine proves effective in Asia
The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease. The late-stage trial involved 10,275 healthy children aged 2-14 across five countries in Asia, a region that accounts for over two-thirds of the mosquito-borne disease's global burden. Sanofi had already disclosed in April that its vaccine reduced the incidence of dengue fever by 56 percent in the Asian study, without giving details. The full findings were published online on Friday in The Lancet medical journal. The study found the vaccine was safe and reduced the most serious cases of haemorrhagic fever by nearly 90 percent. But it offered poor protection to young children - who are most at risk from dengue - and proved notably inefficient in tackling one of the viral disease's four strains. The results suggest the new vaccine acts best as an immune booster for … [Read more...] about Sanofi dengue vaccine promising but questions remain
More than 800,000 school children received the vaccine last year in the world's first public dengue immunisation programme. (Source: Reuters)Hanoi (VNA) - The Philippines isinvestigating the deaths of 14 children which were suspected of being relatedto the dengue vaccine Dengvaxia, the use which was suspended by the government recently,the country’s health officials said on January 5. Health Secretary Francisco Duque said the government has assigned anindependent panel of experts to review the cases and expects their findings inone or two weeks.Assistant Health Secretary Enrique Domingo told reporters that the panel hasbeen asked to investigate the cause of the deaths and whether they are relatedto the vaccination. More than 800,000 school children received the vaccine last year in the world'sfirst public dengue immunisation programme.However, in November last year, Sanofi released findings of a new study thatsaid Dengvaxia could lead to severe infections for vaccinated people … [Read more...] about Philippines probes deaths suspected to be related to dengue vaccine
When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. But the trial also showed that in the third year after receiving the Dengvaxia inoculation, younger children were more likely to end up in hospital with a severe case of dengue than those who didn't get the vaccine. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children. It has also torpedoed … [Read more...] about Did Sanofi, WHO ignore warning signals on dengue vaccine?